May 29, 2020

The Niche

Knoepfler lab stem cell blog

Brief quote from Bob Lanza on Ocata acquisition by Astellas

Robert-LanzaI asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas.

Here’s what he had to say:

“I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for a long list of diseases.”

The day after hearing the news, I myself feel a bit more optimistic that Astellas will continue this important work and help patients with vision impairment as well as other diseases.

%d bloggers like this: